Literature DB >> 19059786

Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2.

Angela J Russell1, Isaac M Westwood, Matthew H J Crawford, James Robinson, Akane Kawamura, Christina Redfield, Nicola Laurieri, Edward D Lowe, Stephen G Davies, Edith Sim.   

Abstract

The identification, synthesis and evaluation of a series of rhodanine and thiazolidin-2,4-dione derivatives as selective inhibitors of human arylamine N-acetyltransferase 1 and mouse arylamine N-acetyltransferase 2 is described. The most potent inhibitors identified have submicromolar activity and inhibit both the recombinant proteins and human NAT1 in ZR-75 cell lysates in a competitive manner. (1)H NMR studies on purified mouse Nat2 demonstrate that the inhibitors bind within the putative active site of the enzyme.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19059786     DOI: 10.1016/j.bmc.2008.11.032

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  20 in total

1.  Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231.

Authors:  Marcus W Stepp; Mark A Doll; Samantha M Carlisle; J Christopher States; David W Hein
Journal:  Mol Carcinog       Date:  2018-02-03       Impact factor: 4.784

Review 2.  Arylamine N-acetyltransferases: a structural perspective.

Authors:  Xiaotong Zhou; Zhiguo Ma; Dong Dong; Baojian Wu
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

3.  Untargeted polar metabolomics of transformed MDA-MB-231 breast cancer cells expressing varying levels of human arylamine N-acetyltransferase 1.

Authors:  Samantha M Carlisle; Patrick J Trainor; Xinmin Yin; Mark A Doll; Marcus W Stepp; J Christopher States; Xiang Zhang; David W Hein
Journal:  Metabolomics       Date:  2016-06-21       Impact factor: 4.290

4.  Metabolic Activation of the Cooked Meat Carcinogen 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine in Human Prostate.

Authors:  Medjda Bellamri; Shun Xiao; Paari Murugan; Christopher J Weight; Robert J Turesky
Journal:  Toxicol Sci       Date:  2018-06-01       Impact factor: 4.849

5.  Three-component, one-flask synthesis of rhodanines (thiazolidinones).

Authors:  Alexander M Jacobine; Gary H Posner
Journal:  J Org Chem       Date:  2011-08-31       Impact factor: 4.354

6.  Identification and characterization of potent, selective, and efficacious inhibitors of human arylamine N-acetyltransferase 1.

Authors:  Carmine S Leggett; Mark A Doll; Raúl A Salazar-González; Mariam R Habil; John O Trent; David W Hein
Journal:  Arch Toxicol       Date:  2021-11-16       Impact factor: 5.153

Review 7.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

8.  A GAA repeat expansion reporter model of Friedreich's ataxia recapitulates the genomic context and allows rapid screening of therapeutic compounds.

Authors:  Michele M P Lufino; Ana M Silva; Andrea H Németh; Javier Alegre-Abarrategui; Angela J Russell; Richard Wade-Martins
Journal:  Hum Mol Genet       Date:  2013-08-13       Impact factor: 6.150

9.  Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars.

Authors:  Isaac M Westwood; Sanjib Bhakta; Angela J Russell; Elizabeth Fullam; Matthew C Anderton; Akane Kawamura; Andrew W Mulvaney; Richard J Vickers; Veemal Bhowruth; Gurdyal S Besra; Ajit Lalvani; Stephen G Davies; Edith Sim
Journal:  Protein Cell       Date:  2010-03-18       Impact factor: 14.870

10.  Prospective virtual screening with Ultrafast Shape Recognition: the identification of novel inhibitors of arylamine N-acetyltransferases.

Authors:  Pedro J Ballester; Isaac Westwood; Nicola Laurieri; Edith Sim; W Graham Richards
Journal:  J R Soc Interface       Date:  2009-07-08       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.